logo-loader
viewAdvanced Oncotherapy PLC

Further re funding for first LIGHT system

/**/ link{ color: blue }visited{ color: #954F72 } .ad{size:595.3pt 841.9pt;margin:2.0cm 42.55pt 2.0cm 42.55pt;}div.ad{}p.bl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: justify}span.bj{color:black}p.bm{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bn{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.bo{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bp{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.bf{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.bq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center} p.br{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: center}p.bs{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}span.bc{color:#0D0D0D}p.bt{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}p.bu{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}table.bv{width:510.35pt;margin-left:-12.5pt;border-collapse:collapse}td.ax{width:231.85pt;padding:0cm 5.4pt 0cm 5.4pt}p.bw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 7.1pt; margin-right: 0cm; margin-top: 0cm}td.av{width:256.9pt;padding:0cm 5.4pt 0cm 5.4pt}p.bx{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right} p.by{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal}p.bz{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: right}td.as{width:300.05pt;padding:0cm 5.4pt 0cm 5.4pt}td.ar{width:188.7pt;padding:0cm 5.4pt 0cm 5.4pt}span.aq{color:black;background:white}td.ap{width:198.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.ao{width:290.75pt;padding:0cm 5.4pt 0cm 5.4pt}td.an{width:179.55pt;padding:0cm 5.4pt 0cm 5.4pt}td.am{width:309.2pt;padding:0cm 5.4pt 0cm 5.4pt}td.al{padding:0cm 0cm 0cm 0cm} td.ak{width:199.5pt;padding:0cm 0cm 0cm 0cm}p.ca{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}span.ag{font-size:11.0pt;line-height:107%;font-family:"Calibri","sans-serif"; color:black}br.ah{page-break-before:always}p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}span.ae{color:black;text-transform:uppercase; letter-spacing:-.1pt} /**/
RNS Number : 0490O
Advanced Oncotherapy PLC
30 September 2019
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").  With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Further re funding for first LIGHT system

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, is pleased to provide an update to its announcement of 7 August 2019 regarding funding for progressing verification and validation activity in order to obtain regulatory approval of its first LIGHT system.

 

The Company is pleased to announce that, due to additional investor demand, the final tranche of the equity fundraise announced on 7 August 2019 has been increased from £2.5 million to approximately £2.9 million. This will result in the issue of 7,364,162 new ordinary shares of 25 pence each ("New Ordinary Shares") at a price of 40 pence per share (the "Issue Price"). 72,912 of these New Ordinary Shares are being issued to a financial adviser in lieu of fees in relation to the fundraising.

 

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will take place on or around 7 October 2019.

 

Total Voting Rights

 

Upon Admission, the Company's enlarged issued share capital will comprise 237,592,656 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights will be 237,592,656. The aforementioned figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0)20 3617 8728

Nicolas Serandour, CEO

 






Allenby Capital Limited (Nominated Adviser & Joint Broker)


Nick Athanas / Liz Kirchner / Nicholas Chambers

 

Tel: +44 (0)20 3328 5656





Stifel Nicolaus Europe (Joint Broker)


Jonathan Senior

 

Tel: +44 (0)20 7710 7600





Walbrook PR (Financial PR & IR)

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001





 

 

 

 

 

 



 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
FURCKCDPCBKDFCB

Quick facts: Advanced Oncotherapy PLC

Price: 37.05

Market: LSE
Market Cap: £88.03 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17